<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806919</url>
  </required_header>
  <id_info>
    <org_study_id>2020-004112-10</org_study_id>
    <nct_id>NCT04806919</nct_id>
  </id_info>
  <brief_title>Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone</brief_title>
  <acronym>PROTECTA</acronym>
  <official_title>Randomized Controlled Trial Comparing Micronized Progesterone (Amelgen ®) 400 mg BID Versus 400 mg TID for Luteal Support in Artificial Vitrified/Warmed Single Blastocyst Transfer Cycles With Low Progesterone on Day of Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the effect of an increased dose of vaginal progesterone&#xD;
      supplementation on the incidence of ongoing pregnancy for patients with a suboptimal serum&#xD;
      progesterone level (defined as &lt; 10 mcg/l) on the day of blastocyst transfer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>7 gestational weeks (+ or - 1 week)</time_frame>
    <description>visualization of an embryo with a heart beat</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometrial impaction: Corelation between the change in endometrial thickness on day of embryo transfer and ongoing pregnancy rate</measure>
    <time_frame>7 gestational weeks (+ or - 1 week)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Questionnaire on patient comfort and side effects</measure>
    <time_frame>On the day of embryo transfer (day 5)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire on patient comfort and side effects</measure>
    <time_frame>On the day of the initial pregnancy test (day 16 (± 2 days))</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>IVF</condition>
  <condition>Embryo Loss</condition>
  <condition>Luteal Phase Defect</condition>
  <arm_group>
    <arm_group_label>Control group: Amelgen ® 400 mg BID</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continue daily dose progesteron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group: Amelgen ® 400 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increase daily progesteron dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesteron TID</intervention_name>
    <description>increasing the dose</description>
    <arm_group_label>Intervention group: Amelgen ® 400 mg TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent form (ICF) dated and signed&#xD;
&#xD;
          -  Age ≥ 18 and &lt; 40 years old&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.5 kg/m2 and &lt; 35 kg/m2&#xD;
&#xD;
          -  Less than 4 previous Assisted Reproductive Technologies (ART) cycles&#xD;
&#xD;
          -  Current pregnancy wish&#xD;
&#xD;
          -  Patients undergoing a single vitrified/warmed single transfer in an artificial&#xD;
             prepared endometrium cycle (IVF or ICSI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Simultaneous participation in another clinical study&#xD;
&#xD;
          -  Previous participation in this study&#xD;
&#xD;
          -  Known reasons for impaired implantation (specifically: presence of a hydrosalpinx;&#xD;
             presence of a type I, II or III fibroid; Asherman's syndrome; uterine malformations,&#xD;
             intrauterine adhesions, ≥ grade 3 endometriosis according to the ASRM classification,&#xD;
             endometrial tuberculosis)&#xD;
&#xD;
          -  Repeated miscarriages (&gt; 2 previous biochemical pregnancies or &gt; 2 spontaneous&#xD;
             miscarriages)&#xD;
&#xD;
          -  Untreated and uncontrolled thyroid dysfunction&#xD;
&#xD;
          -  Tumors of the ovary, breast, uterus, pituitary or hypothalamus&#xD;
&#xD;
          -  Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause&#xD;
&#xD;
          -  Ovarian cysts or enlarged ovaries&#xD;
&#xD;
          -  Fibroid tumors of the uterus incompatible with pregnancy&#xD;
&#xD;
          -  Malformations of the reproductive organs incompatible with pregnancy&#xD;
&#xD;
          -  Previous antibiotic hypersensitivity reactions (streptomycin and/or neomycin)&#xD;
&#xD;
          -  Risk factors for thromboembolic events, such as a personal or family history, severe&#xD;
             obesity or thrombophilia&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  Ongoing pregnancy&#xD;
&#xD;
          -  Use of carbamazepine, rifampicin or phenytoin&#xD;
&#xD;
          -  Those unable to comprehend the investigational nature of the proposed study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Stoop</last_name>
      <phone>09/332.16.99</phone>
      <email>dominic.stoop@uzgent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embryo Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

